Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration-Reference-Cited by-同舟云学术

Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration

Published:2020-02-27 Issue:3 Volume:41 Page:393-399
ISSN:0195-6108
Container-title:American Journal of Neuroradiology
language:en
Short-container-title:AJNR Am J Neuroradiol

Author:

Kanal E.^ORCID,Patton T.J.^ORCID,Krefting I.^ORCID,Wang C.^ORCID

Funder

U.S. Food and Drug Administration

Publisher

American Society of Neuroradiology (ASNR)

Subject

Clinical Neurology,Radiology Nuclear Medicine and imaging

Reference36 articles.

1. Balzer T . Presence of Gadolinium (Gd) in the Brain and Body: Presentation to the Medical Imaging Drugs Advisory Committee, September 8, 2017. FDA. Silver Spring, Md: U.S. Food and Drug Administration. https://www.fda.gov/media/107670/download. Accessed February 5, 2020

2. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates

3. Gadolinium deposition in nephrogenic fibrosing dermopathy

4. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

5. Diagnosis of Nephrogenic Systemic Fibrosis by means of Elemental Bioimaging and Speciation Analysis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The magnetic resonance imaging characteristics of radicular cysts and granulomas;Dentomaxillofacial Radiology;2023-02

2. Dose‐Lowering in Contrast‐Enhanced MRI of the Central Nervous System: A Retrospective, Parallel‐Group Comparison Using Gadobenate Dimeglumine;Journal of Magnetic Resonance Imaging;2021-05-20

3. Can Hybrid Arterial Spin Labeling‐Tagged Zero‐Echo‐Time Magnetic Resonance Angiography Be an Effective Candidate in the Evaluation of Intracranial Artery Diseases? A Clinical Feasibility Study;Journal of Magnetic Resonance Imaging;2021-05-20

4. Group II GBCM Can Be Used Safely for Imaging in Stage 4/5 CKD Patients: COMMENTARY;Kidney360;2020-12-03

5. Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents;Annals of Internal Medicine;2020-07-21